Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.

Martin J. Van Den Bent, Martin Klein, Marion Smits, Jaap C. Reijneveld, Ahmed Idbaih, Paul Clement, Filip Yves Francine Leon De Vos, Wolfgang Wick, Paul James Mulholland, Martin J. B. Taphoorn, Joanne Lewis, Iris de Heer, Johan M. Kros, Tina Verschuere, Vassilis Golfinopoulos, Thierry Gorlia, Pim French

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of clinical oncology
Publication statusPublished - 20 May 2017

Cite this